Novo Nordisk A/S' NVO Canada unit on Thursday announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental new drug submission (sNDS) for semaglutide 2.4 mg
Novo Nordisk A/S' NVO Canada unit on Thursday announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental new drug submission (sNDS) for semaglutide 2.4 mg
Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports that
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
A reclusive firm is often considered the world's most successful hedge fund. That company is Renaissance Technologies.
I'm going on a 2-week vacation with my family for my sister's wedding, so I've prepared a comprehensive article with three types of dividend aristocrat recommendations for whateveriscomingnext. Low-vo

Is Novo Nordisk Stock a Buy?

06:45am, Friday, 02'nd May 2025
For years, Denmark-based Novo Nordisk (NVO -1.19%) was a fairly traditional develop-and-market pharmaceutical company that escaped notice by many investors. Though listed on American stock exchanges,
Novo Nordisk A/S NVO announced that CVS Health Inc's CVS CVS Caremark, a Pharmacy Benefit Manager (PBM), has decided that Wegovy (semaglutide) injection 2.4 mg will soon be the preferred GLP-1 med
CVS Health Corp CVS reported first-quarter sales of $94.59 billion on Thursday, beating the consensus of $93.64 billion.

Why Novo Nordisk Stock Popped Today

11:11am, Thursday, 01'st May 2025
Novo Nordisk (NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m.
CVS Health said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Under a new partnership between Caremark

Novo Nordisk: The Fear Is Overblown

02:24am, Thursday, 01'st May 2025
Novo Nordisk's about 55% stock decline since June 2024 is driven by clinical trial misses, increasing competition, and geopolitical turbulence. Due to the compressed valuation, Novo Nordisk needs to g
Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.
Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo Nordi
The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only getting wider.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE